盛禾生物委任姜晓玲为CEO兼首席科学官，履历涵盖金斯瑞、优科制药

Group 1 - The core point of the article is the appointment of Jiang Xiaoling as the CEO and Chief Scientific Officer of Shenghe Biopharma, effective from January 23, 2026 [2] - Jiang Xiaoling has been with the company since February 2020, previously serving as the Deputy General Manager and Head of R&D at Shenghe (China) Biopharma [2] - Jiang Xiaoling has a strong background in biopharmaceuticals, having worked in various roles related to drug development and research since 2007 [2][3] Group 2 - Shenghe Biopharma focuses on discovering, developing, and commercializing innovative biopharmaceuticals that modulate the immune microenvironment [3] - The company reported other income of 5.035 million in the first half of 2025, representing a year-on-year increase of 182.55% [3] - Shenghe Biopharma incurred a loss of 38.199 million in the same period, compared to a loss of 36.077 million in the previous year [3]